Amgen
3Q Revenues: $5.7 billion (-3%)
3Q Earnings: $2.0 billion (+6%)
YTD Revenues: $17.2 billion (-2%)
YTD Earnings: $6.1 billion (-5%)  
Comments: Enbrel sales were $1.4 billion in the quarter, up 6%. Prolia sales were up 18% to $630 million. Repatha sales were up 40% to $168 million. Aimovig sales totaled $66 million in the quarter. Parsabiv sales were up 54% to $157 million. KYPROLIS sales were $266 million, up 15%. BLINCYTO sales were up 47% to $85 million. Growth was offset by declines for flagship products. Neulasta, sales were down 32% to $711 million. Neupogen sales were down 36% to $54 million. Epogen sales were down 15% to $215 million. Aranesp sales were down 5% to $452 million. Sensipar/Mimpara sales were down 73% to $109 million